Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 3/20 | 0.64 |
| ▸ | ECE1 | P42892 | 7/20 | 0.60 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.59 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | MPO | P05164 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | BLM | P54132 | 1/20 | 0.59 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5822565 | 1.00 | ACE (0.64) | ACEECE1ERAP2ALOX15KDM4E | |
| SCHEMBL5970197 | 1.00 | ACE (0.64) | ACEECE1ERAP2ALOX15KDM4E | |
| SCHEMBL5735540 | 1.00 | ACE (0.64) | ACEECE1ERAP2ALOX15KDM4E | |
| SCHEMBL3053752 | 1.00 | ACE (0.64) | ACEECE1ERAP2ALOX15KDM4E | |
| SCHEMBL15004878 | 0.99 | ACE (0.63) | ACEECE1ERAP2ALOX15KDM4E | |
| SCHEMBL30997441 | 0.97 | ACE (0.61) | ACEECE1ERAP2ALOX15KDM4E | |
| SCHEMBL30903469 | 0.95 | ERAP2 (0.60) | ACEECE1ERAP2ALOX15KDM4E | |
| SCHEMBL17941661 | 0.94 | LTA4H (0.59) | ACEERAP2KMT2A | |
| SCHEMBL17941660 | 0.94 | LTA4H (0.59) | ACEERAP2KMT2A | |
| SCHEMBL30284429 | 0.94 | ERAP2 (0.64) | ACEECE1ERAP2ALOX15KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 133 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3987064-A1 | METHOD FOR DIAGNOSING ESTHETIC DEGRADATIONS OF SKIN | L'OREAL (FR) | 2022-04-27 | — | — | EP | claimed |
| WO-2020260355-A1 | METHOD FOR DIAGNOSING ESTHETIC DEGRADATIONS OF SKIN | L'OREAL (FR) | 2020-12-30 | — | — | WO | claimed |
| WO-2012068412-A2 | METHOD AND COMPOSITIONS FOR TREATMENT OF STAT3-RESPONSIVE CANCERS AND/OR RENAL CANCER | SCICLONE PHARMACEUTICALS, INC. (US) | 2012-05-24 | — | — | WO | claimed |
| EP-1814566-B1 | TREATMENT OR PREVENTION OF HEMORRHAGIC VIRAL INFECTIONS WITH IMMUNOMODULATOR COMPOUNDS | SCICLONE PHARMACEUTICALS INC (US) | 2010-07-28 | — | — | EP | claimed |
| US-20030087830-A1 | Low molecular weight components of cartilage, complexes of metals with amino acids, DI-peptides and analogs thereof; processes for preparation and therapeutic uses thereof | AETERNA ZENTARIS INC. (CA) | 2003-05-08 | — | — | US | claimed |
| WO-2002100421-A1 | LOW MOLECULAR WEIGHT COMPONENTS OF CARTILAGE, COMPLEXES OF COPPER WITH AMINO ACIDS OR DI-PEPTIDES; PROCESSES FOR PREPARATION AND THERAPEUTIC USES THEREOF | LES LABORATOIRES AETERNA INC. (CA) | 2002-12-19 | — | — | WO | claimed |
| WO-1998009989-A1 | THE USE OF MURAMYLPEPTIDES IN THE TREATMENT OF MYELOSUPPRESSED OR OTHERWISE IMMUNOCOMPROMISED STATES | PEPTECH (UK) LIMITED (GB) | 1998-03-12 | — | — | WO | claimed |
| EP-0722332-A1 | COMPOUNDS FOR MEDICINAL USE | PEPTECH (UK) LIMITED (GB) | 1996-07-24 | — | — | EP | claimed |
| WO-1995010293-A1 | COMPOUNDS FOR MEDICINAL USE | PEPTECH (UK) LIMITED (GB) | 1995-04-20 | — | — | WO | claimed |
| EP-0457314-A1 | Nutrient compositions containing peptides | CLINTEC NUTRITION COMPANY (US) | 1991-11-21 | — | — | EP | claimed |
| JP-6078687-A | — | — | None | — | — | JP | disclosed |
| WO-2026086694-A1 | PEDIATRIC COMPOUND AMINO ACID INJECTION AND PREPARATION METHOD THEREFOR | 四川科伦药业股份有限公司 | 2026-04-30 | — | — | WO | disclosed |
| EP-3604503-B1 | ADDITIVE FOR UNDIFFERENTIATION MAINTAINING MEDIUM | AJINOMOTO KK (JP) | 2026-03-18 | — | — | EP | disclosed |
| US-20250270512-A1 | ADDITIVE FOR UNDIFFERENTIATION MAINTAINING MEDIUM | AJINOMOTO CO., INC. (JP) | 2025-08-28 | — | — | US | disclosed |
| US-12383628-B2 | Hydrogel-forming composition for controlled release | VRIJE UNIVERSITEIT BRUSSEL (BE) | 2025-08-12 | — | — | US | disclosed |
| US-5744452-A | IMMUNE SYSTEM DISORDERS, AIDS | Wei, Edward T. (US) | 1998-04-28 | — | — | US | disclosed |
| US-5728680-A | ADMINISTERING GLUTAMIC ACID-TRYPTOPHAN DIPEPTIDE; IMMUNOMODULATION | CYTOVEN J.V. (US) | 1998-03-17 | — | — | US | disclosed |
| WO-1997019691-A1 | GAMMA-L-GLUTAMYL CONTAINING IMMUNOMODULATOR COMPOUNDS AND METHODS THEREWITH | WEI, EDWARD, T. (US) | 1997-06-05 | — | — | WO | disclosed |
| WO-1995003067-A1 | PHARMACEUTICAL WITH IMMUNOMODULATING ACTIVITY | KHAVINSON VLADIMIR KHATSKELEVI (RU) | 1995-02-02 | — | — | WO | disclosed |
| JP-H0678687-A | FEED FOR CRUSTACEANS | NKK CORP | 1994-03-22 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030087830-A1 | Low molecular weight components of cartilage, complexes of metals with amino acids, DI-peptides and analogs thereof; processes for preparation and therapeutic uses thereof | TIE1, TEK, VEGFA | ACE 1848/4885ECE1 830/4885ERAP2 549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.